These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Endorphins in psychiatry]. Lajeunesse C; Villeneuve A Sem Hop; 1982 Dec; 58(44):2581-7. PubMed ID: 6297051 [No Abstract] [Full Text] [Related]
4. [Endorphins. Physiological and pharmacological aspects, and research in psychiatry]. Leboyer M Encephale; 1986; 12(2):45-62. PubMed ID: 3527685 [TBL] [Abstract][Full Text] [Related]
6. Carbidopa-levodopa therapy for movement disorders. Sohn DG; Hoerning E; Kaplan PE Arch Phys Med Rehabil; 1987 Oct; 68(10):745-6. PubMed ID: 3662785 [No Abstract] [Full Text] [Related]
7. Opioid switching and burst ketamine to improve the opioid response in patients with movement-related pain due to bone metastases. Mercadante S; Villari P; Ferrera P; Arcuri E; David F Clin J Pain; 2009 Sep; 25(7):648-9. PubMed ID: 19692808 [TBL] [Abstract][Full Text] [Related]
8. Movement disorders in geriatric rehabilitation. Camicioli R Clin Geriatr Med; 1993 Nov; 9(4):765-81. PubMed ID: 8281504 [TBL] [Abstract][Full Text] [Related]
9. Ablative therapy for movement disorders. Complications in the treatment of movement disorders. Louw DF; Burchiel KJ Neurosurg Clin N Am; 1998 Apr; 9(2):367-73. PubMed ID: 9495898 [TBL] [Abstract][Full Text] [Related]
10. [Etiologic and therapeutic significance of endorphins in endogenous psychoses]. Naber D Nervenarzt; 1983 Nov; 54(11):573-7. PubMed ID: 6318141 [No Abstract] [Full Text] [Related]
11. Behavioral and neuroendocrine effects of opioid receptor agonists in psychopathologic states. Judd LL; Risch SC; Segal DS; Janowsky DS; Huey LY Psychiatr Clin North Am; 1983 Sep; 6(3):393-402. PubMed ID: 6359090 [No Abstract] [Full Text] [Related]
12. Experimental therapeutics of movement disorders. Adv Neurol; 1983; 37():1-319. PubMed ID: 6858767 [No Abstract] [Full Text] [Related]
13. [Importance of the discovery of endorphins and enkephalins for present-day psychopharmacology]. Herman ZS Postepy Hig Med Dosw; 1983; 37(3):233-70. PubMed ID: 6143307 [No Abstract] [Full Text] [Related]
14. [Experience with pharmacotherapy of central movement disorders in children]. Nachtmann M; Stehlík A Cesk Pediatr; 1989 Sep; 44(9):536-8. PubMed ID: 2805133 [No Abstract] [Full Text] [Related]
15. [Practical considerations regarding the diagnosis and treatment of disorders of movement in childhood]. Fernández-Alvarez E; Campos-Castelló J Rev Neurol; 2000 Aug 16-31; 31(4):349-53. PubMed ID: 11008290 [TBL] [Abstract][Full Text] [Related]
16. [Endorphins between psychosomatics and psychiatric therapy]. Messini P Clin Ter; 1988 Jan; 124(2):139-44. PubMed ID: 2973924 [No Abstract] [Full Text] [Related]
17. Opioid agonists and antagonists in schizophrenia. Barchas JD; Berger PA; Watson SJ; Akil H; Li CH Adv Biochem Psychopharmacol; 1980; 22():447-53. PubMed ID: 7395601 [No Abstract] [Full Text] [Related]
18. [Medical therapy of nonparkinsonian dyskinesias]. Thomson AF Arch Fund Roux Ocefa; 1974; 8(1-4):139-44. PubMed ID: 4458627 [No Abstract] [Full Text] [Related]
19. [Lars Terenius on neuropeptides and pain: endorphins diminish stress--a curative effect? A new analgesic aimed at the spinal region. Interview by Birgit Lindell]. Terenius L Lakartidningen; 1984 Dec; 81(49):4650-3. PubMed ID: 6097783 [No Abstract] [Full Text] [Related]
20. Study of the prevalence and therapy of the choreatiform syndrome or hyperkinesis in rural Vermon. Huessy HR Acta Paedopsychiatr; 1967; 34(4):130-5. PubMed ID: 4874369 [No Abstract] [Full Text] [Related] [Next] [New Search]